CDH1 c‐160a promotor polymorphism is not associated with risk of stomach cancer
Open Access
- 26 July 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 101 (2), 196-197
- https://doi.org/10.1002/ijc.10590
Abstract
We have combined data from case control studies designed to test the hypothesis that the c‐160a promotor polymorphism in the gene coding for the cell adhesion molecule E‐cadherin (CDH1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype‐specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98–1.8) and 1.2 (0.68–2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal‐ and diffuse‐type histopathologic subgroups.Keywords
This publication has 5 references indexed in Scilit:
- Association of the −160 C → a promoter polymorphism of E‐cadherin gene with gastric carcinoma riskCancer, 2002
- CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer riskInternational Journal of Cancer, 2001
- Diffuse Type Gastric and Lobular Breast Carcinoma in a Familial Gastric Cancer Patient with an E-Cadherin Germline MutationThe American Journal of Pathology, 1999
- Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal CancerHuman Molecular Genetics, 1999
- E-cadherin germline mutations in familial gastric cancerNature, 1998